TITAN Trial: A Randomized Controlled Trial of a Cardiac Rehabilitation Care Model in Breast Cancer
Authors' conclusion
The CR-modeled intervention had no effect on LVEF or biomarkers of cardiotoxicity.
Study context
- Population
- Patients with stage I–III breast cancer scheduled for anthracycline and/or trastuzumab-based chemotherapy
- Participants
- 37 vs 37
- Comparison
- Multidisciplinary cardiac rehabilitation (CR)-modeled intervention vs usual care
- CR interventionn = 37
- Usual caren = 37reference
- Primary endpoint
- LVEF
- Follow-up
- 52 weeks
Primary result
As reported in the abstract
No difference in left ventricular ejection fraction (LVEF) between groups
61% ± 6%
Further findings
High-sensitivity troponin I and BNP
- Similar between groups
Total cholesterol (baseline to 52 weeks)
- Decreased in CR intervention, 5.2 ± 0.8 to 4.7 ± 0.8 mmol/L
- P = 0.002
- Unchanged in Usual care
LDL (baseline to 52 weeks)
- Decreased in CR intervention, 3.0 ± 0.7 to 2.4 ± 0.7 mmol/L
- P < 0.001
- Unchanged in Usual care
Cardiac and metabolic changes, all patients · 52 weeks
- Reductions in LVEF, LV mass, HDL, lean body mass, IGF-1; increased TG, whole-body and truncal fat mass
- all P < 0.050
Original publication
TITAN Trial: A Randomized Controlled Trial of a Cardiac Rehabilitation Care Model in Breast Cancer. JACC Adv. Published 27 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →